Syngene International Limited — PPTs, 12-03-2025: Investor Presentation

**Financial Highlights:** Syngene International reports sustained revenue growth, achieving INR 50,239 million in FY24, reflecting a CAGR of 15% since FY18. Operating EBITDA margins remain robust, consistently in the high 20s. The company witnessed a net cash position increase to INR 9,353 million, despite ongoing strategic investments to enhance growth.

**Strategic Initiatives and Growth Drivers:** Upcoming initiatives include expanding biologics capabilities and commercial manufacturing partnerships, particularly in the US market, which is projected to grow at 10-12% CAGR. There's a focus on converting pilot projects into long-term contracts and addressing the needs of mid/small biotech firms.

**Business Developments:** The acquisition of Emergent’s Bayview site for USD 50 million aims to strengthen Syngene's presence in the US, catering to both human and animal health sectors. This site complements ongoing processes in India, though initial years may see margin dilution as utilization ramps up.

**Market Position and Competitive Advantage:** Positioned as a leader in India’s CRO and biomanufacturing sectors, Syngene serves 14 of the top 20 pharmaceutical companies globally. The company’s comprehensive capabilities in small and large molecule CDMO services provide a competitive edge in a growing CRDMO market.

**Investor Implications:** With a strong financial standing and key expansions underway, Syngene is well-placed for future growth. The strong demand in the CRDMO market offers investors a positive outlook as the company continues to innovate and expand its capabilities.